|

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

RECRUITINGN/ASponsored by Chang Gung Memorial Hospital
Actively Recruiting
PhaseN/A
SponsorChang Gung Memorial Hospital
Started2022-08-01
Est. completion2028-07-31
Eligibility
Age30 Years – 80 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06232122

Summary

A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy

Eligibility

Age: 30 Years – 80 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Pathologically proven ovarian cancer with complete response after therapy
* Age between 30 and 80
* Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
* ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
* Willing to enter this prospective study with signed informed consent form

Exclusion Criteria:

* Patients with history of other malignancy
* Patients who are pregnant or lactating
* Patients with fasting fingerstick glucose level higher than 200 mg/dl
* Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
* Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators

Conditions2

CancerOvarian Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.